Search This Blog

Tuesday, October 6, 2020

Biocept up 3% on demand for COVID-19 test

Biocept (NASDAQ:BIOC) announces that it has received more than 50K COVID-19 specimens for testing for the presence of SARS-CoV-2 via its in-house molecular test, adding that demand continues to build.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)